Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enliven Therapeutics, Inc. - Common Stock (NQ: ELVN )

25.41 -0.02 (-0.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enliven Therapeutics, Inc. - Common Stock

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024
ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024
ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data. 
Via Benzinga
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho... 
Via Benzinga
Wall Street Mixed As Tech Stocks Fall, Fed Meeting Begins
Stocks are scattered midday Tuesday, as investors digest the semiconductor sector's pullback that's being led by the shares of Nvidia. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. 
Via Benzinga
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023
ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
7 A-Rated Biotech Stocks for Your August Buy List
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
Via InvestorPlace
Bears Reload On Mobileye After Sharp Gains In Stock Price
Short interest on Mobileye Global fell from 23.9% to 21.2% in the week following the company’s Q1 results and FY23 guidance cut on April 27. However, Mobileye shares are up 31% from those lows over the... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
Via Benzinga
7 Biotech Stocks Sitting in the Sweet Spot
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.